Business Description
Coherus Oncology is a US-based biopharmaceutical company focused on developing and selling cancer treatments, including approved therapies and drugs still in clinical testing. Its portfolio includes a biosimilar supporting immune recovery during chemotherapy, an approved checkpoint inhibitor for certain head and neck cancers, and several experimental antibody-based therapies targeting the tumor environment. The company works alongside a number of partners, including Junshi Biosciences, Novartis, and GlaxoSmithKline, through licensing and co-development agreements. Founded in 2010 and headquartered in Redwood City, California, the company rebranded under its current name in May 2025.
